Insight Molecular Diagnostics Inc. IMDX 深 滬
已收盤 02-06 16:00:00 美东时间
7.32
+0.630
+9.42%
華盛通- 最 高7.48
- 今 開6.73
- 成交量 6.15万股
- 最 低 6.54
- 昨 收 6.69
- 總市值 2.10亿
- 52周最高 8.51
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 2.3205
- 委 比 59.35%
- 總股本 2866.44万
- 歷史最高 204.80
- 量 比 3.70
- 振 幅 14.05%
- 歷史最低 1.922
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
Insight Molecular Diagnostics Inc. (iMDx) congratulated the STAR working group for its position paper in the *American Journal of Transplantation*, which emphasizes the importance of decentralized dd-cfDNA testing for transplant patients. The paper highlights the need for standardized, high-quality testing to support multicenter studies and real-world evidence generation, aligning with iMDx's strategy to decentralize organ health testing. iMDx CE...
01-13 14:00
Insight Molecular Outlines Commercial Gains, FDA De Novo Submission Plans For GraftAssureDx In 2026
GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at
01-05 20:04
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Needham Maintains Buy on Insight Molecular, Raises Price Target to $9
Needham analyst Mike Matson maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the price target from $4.25 to $9.
2025-11-11 19:01
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
Insight Molecular Diagnostics Inc. (iMDx) announced the appointment of Steven Tahmooressi as Vice President of Marketing. He brings over 25 years of experience in new product adoption across transplantation, oncology, and immunology. Tahmooressi will lead global marketing efforts for the GraftAssure family of assays and future products. iMDx is preparing to launch its first clinical kitted assay, GraftAssureDx, in 2026. The company aims to expand...
2025-10-13 20:05
Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Monitoring High-Risk Kidney Transplant Patient
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid
2025-10-06 19:20
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
A study published in the American Journal of Transplantation highlights the essential role of GraftAssure in managing kidney transplant patients with certain cancers, particularly in avoiding overtreatment and preserving immune function. The study details a unique case where GraftAssure molecular testing confirmed the absence of organ rejection during novel CD19 CAR-T therapy for a patient with lymphoma, enabling sustained graft health and oncolo...
2025-10-06 11:15
Insight Molecular Diagnostics Extends Executive Employment Agreement
Insight Molecular Diagnostics ( ($IMDX) ) just unveiled an update. On September...
2025-10-03 04:35
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
Insight Molecular Diagnostics Inc. (iMDx) will present its GraftAssureIQ research-use-only test kit and discuss the clinical potential of its GraftAssure technology at two major conferences. At the IATDMCT annual meeting in Singapore, the company will host a symposium on September 24 to highlight how GraftAssureIQ can improve transplant rejection detection and treatment monitoring. In Orlando, iMDx and its partner Bio-Rad will present on October ...
2025-09-24 11:05
